Business Description
Novavax Inc
NAICS : 325414
SIC : 2836
ISIN : US6700024010
Total Employee Number:
749Compare
Compare
Traded in other countries / regions
NVAX.USANVV1.GermanyNVAX.AustriaNVAX.MexicoNVV1.BulgariaNVAX.Switzerland IPO Date
2024-09-26Description
Novavax Inc. is a commercial-stage biotechnology company that develops and commercializes vaccines for infectious diseases. Its flagship product, NVX-CoV2373 (Nuvaxovid), is a protein-based COVID-19 vaccine adjuvanted with Matrix-M, its proprietary saponin-based adjuvant technology. The company also develops vaccine candidates targeting influenza, COVID-19/influenza combination, and other infectious diseases, and has pursued programs against respiratory syncytial virus and other pathogens. Novavax sells its COVID-19 vaccine in the United States and internationally, including through partnerships and advance purchase agreements with governments and organizations such as Gavi and the Serum Institute of India, which manufactures and distributes the vaccine in certain markets. Revenue derives primarily from product sales and licensing, royalty, and collaboration agreements. The company operates as a single reportable segment and is headquartered in Gaithersburg, Maryland.
Financial Strength
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 2.42 | |||||
Equity-to-Asset | -0.2 | |||||
Debt-to-Equity | -1.56 | |||||
Debt-to-EBITDA | -1.45 | |||||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | -5.76 | |||||
Beneish M-Score | -4.41 | |||||
WACC vs ROIC | ||||||
Growth Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -31.8 | |||||
3-Year FCF Growth Rate | 39.4 | |||||
3-Year Book Growth Rate | 52.6 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | -35.61 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 69.18 | |||||
9-Day RSI | 64.89 | |||||
14-Day RSI | 63.04 | |||||
3-1 Month Momentum % | -17.05 | |||||
6-1 Month Momentum % | -24.13 | |||||
12-1 Month Momentum % | -5.52 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.33 | |||||
Quick Ratio | 2.3 | |||||
Cash Ratio | 2.18 | |||||
Days Inventory | 46.8 | |||||
Days Sales Outstanding | 72.17 | |||||
Days Payable | 106.72 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -23.6 | |||||
Shareholder Yield % | -2.76 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 78.6 | |||||
Operating Margin % | -32.93 | |||||
Net Margin % | -59.87 | |||||
EBITDA Margin % | -49.68 | |||||
FCF Margin % | -8.36 | |||||
OCF Margin % | -6.93 | |||||
ROA % | -21.76 | |||||
ROIC % | -26.44 | |||||
3-Year ROIIC % | -70.9 | |||||
ROC (Joel Greenblatt) % | -205.02 | |||||
ROCE % | -29.87 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 4 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 34.5 | |||||
PS Ratio | 4.02 | |||||
EV-to-EBIT | -5.64 | |||||
EV-to-EBITDA | -6.12 | |||||
EV-to-Revenue | 3.05 | |||||
EV-to-Forward-Revenue | 2.7 | |||||
EV-to-FCF | -26.3 | |||||
Price-to-GF-Value | 3.24 | |||||
Price-to-Median-PS-Value | 0.39 | |||||
Earnings Yield (Greenblatt) % | -17.71 | |||||
FCF Yield % | -2.55 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Novavax Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 354.709 | ||
| EPS (TTM) (€) | -1.304 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 70.29 | ||
| 14-Day RSI | 63.04 | ||
| 14-Day ATR (€) | 0.369791 | ||
| 20-Day SMA (€) | 8.395 | ||
| 12-1 Month Momentum % | -5.52 | ||
| 52-Week Range (€) | 5.406 - 9.88 | ||
| Shares Outstanding (Mil) | 164.95 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Novavax Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Novavax Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Fourth quarter earnings conference call for 2026 | 2027-02-26 08:30 | In 158 days | ||
| Annual report for 2026 | 2027-02-26 | In 157 days | ||
| Fourth quarter earnings results for 2026 | 2027-02-26 | In 157 days | ||
| Third quarter earnings conference call for 2026 | 2026-11-06 08:30 | In 46 days | ||
| Third quarter earnings results for 2026 | 2026-11-06 | In 45 days | ||
| Guidance call for 2026 | 2026-09-10 10:00 | 8.42 (-4.64%) | ||
| Guidance call for 2026 | 2026-09-09 09:45 | 8.68 (-0.80%) | ||
| Second quarter earnings conference call for 2026 | 2026-08-06 08:30 | 6.64 (-0.45%) | ||
| Second quarter earnings results for 2026 | 2026-08-06 | 6.64 (-0.45%) | ||
| General meeting for 2026 | 2026-06-18 08:30 | 8.12 (+1.88%) |
Show
Entries
Novavax Inc Frequently Asked Questions
What is Novavax Inc(WBO:NVAX)'s stock price today?
The current price of WBO:NVAX is €9.08. The 52 week high of WBO:NVAX is €9.88 and 52 week low is €5.41.
When is next earnings date of Novavax Inc(WBO:NVAX)?
The next earnings date of Novavax Inc(WBO:NVAX) is 2026-11-06 Est..
Does Novavax Inc(WBO:NVAX) pay dividends? If so, how much?
Novavax Inc(WBO:NVAX) does not pay dividend.
Press Release
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers